DUBLIN – Shares in Auris Medical AG (Nasdaq:EARS) plummeted more than 60 percent during premarket trading Tuesday on news that its lead drug candidate, AM-111, missed the primary endpoint of a phase III trial, called Healos, in patients who experienced sudden deafness.